

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

FAGER, Gunnar

Atty. Ref.: 3764-120

Serial No. Unassigned

Group:

Filed: March 18, 2002

Examiner:

For: **NEW DIALYSIS METHOD**

\* \* \* \* \*

March 18, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

Please amend the above-identified application as follows:

**IN THE CLAIMS**

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

4. (Amended) The use as claimed in Claim 1, wherein the dialysis is haemodialysis.

8. (Amended) A solution according to Claim 5, a concentrate as defined above, or a kit of parts Claim 1, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino-acid based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

11. (Amended) A process for the preparation of a solution, or a concentrate, as defined in Claim 5, which comprises admixing a formulation including a low molecular weight thrombin inhibitor (or prodrug thereof) and a dialysis solution, or a dialysis concentrate (as appropriate).


**REMARKS**

The above amendments have been made to place the application in a more traditional format. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS**

4. (Amended) The use as claimed in [any one of Claims 1 to 3] Claim 1, wherein the dialysis is haemodialysis.

8. (Amended) A solution according to Claim 5, a concentrate [according to Claim 6] as defined above, or a kit of parts [according to Claim 7 as defined above, wherein the dialysis is haemodialysis.

9. (Amended) A use, solution, concentrate, or kit of parts, as claimed in [any one of Claims 1 to 8 (as appropriate)] Claim 1, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino-acid based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

11. (Amended) A process for the preparation of a solution, or a concentrate, as defined in [any one of Claims 5, 6 or 8 to 10 (as appropriate)] Claim 5, which comprises admixing a formulation including a low molecular weight thrombin inhibitor (or prodrug thereof) and a dialysis solution, or a dialysis concentrate (as appropriate).